High flow nasal cannula market seen reaching $9.64 billion by 2030

The high flow nasal cannula market is projected to grow from $6.22 billion in 2025 to $6.79 billion in 2026, with North America holding the largest share last year. The Business Research Company says rising respiratory disease cases, home-care adoption and portable device demand are driving the next phase of growth.

Why it matters: - High flow nasal cannula devices are becoming a bigger part of respiratory care as hospitals and home-care settings look for more effective oxygen delivery. - The market’s projected climb to $9.64 billion by 2030 signals sustained demand for non-invasive oxygen therapy and related respiratory technologies. - Rising cases of asthma and COPD are increasing the patient pool that may need high-flow oxygen support.

What happened: - The Business Research Company published a market outlook on the high flow nasal cannula market. - The market is projected to rise from $6.22 billion in 2025 to $6.79 billion in 2026, a 9.3% CAGR. - The report forecasts the market will reach $9.64 billion by 2030, at a 9.2% CAGR. - North America held the largest regional share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - High flow nasal cannula, or HFNC, delivers oxygen-enriched, heated and humidified air at high flow rates. - The device uses a lightweight tube connected to a machine that controls air and oxygen flow. - The cannula sits in the nostrils and delivers continuous warm, moist air above conventional oxygen therapy levels. - The report links recent growth to more respiratory disease, more hospital admissions for acute respiratory failure, wider use of high-flow oxygen therapy protocols, growth in intensive care capacity and better clinical understanding of HFNC benefits. - The forecast period is expected to be driven by home-care use, portable respiratory devices, respiratory care service expansion, early intervention treatment and improvements in airflow regulation and humidification. - The report highlights growing adoption of advanced heated humidification, stronger use in acute care, broader preference for non-invasive oxygen therapies, more portable and home-based devices and greater emphasis on patient comfort and compliance. - HFNC can improve oxygen levels while reducing heart rate and respiratory rate in severe bronchial asthma complicated by respiratory failure. - A December 2023 study in JAMA Network Open projected global COPD cases could approach nearly 600 million by 2050, a 23% increase in prevalence. - The report also says updated 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis. - The report is available through the full market report. - A free sample is available through the sample report.

Between the lines: - The market forecast points to a shift beyond hospital-only use, with home care and portability emerging as major growth themes. - The emphasis on humidification and comfort suggests vendors are competing on usability as much as clinical performance. - The COPD projection helps explain why oxygen-delivery devices remain a long-term respiratory care priority rather than a short-term pandemic-era trend.

What's next: - Growth is expected to continue as healthcare systems expand respiratory care capacity and adopt more home-based treatment options. - Product development will likely center on better airflow control, improved humidification and easier-to-use portable devices. - Regional growth beyond North America will depend on healthcare access and respiratory care adoption in emerging markets.

The bottom line: - HFNC is moving from a specialized hospital tool to a broader respiratory care category with clear growth in acute, portable and home-use settings.